Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 250 results for carcinoma

  1. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued [GID-TA10164]

    Technology appraisal guidance
    Discontinued

  2. Laparoscopic cryotherapy for renal cancer (IPG405)

    Evidence-based recommendations on laparoscopic cryotherapy for renal cancer. This involves inserting a surgical instrument (cryoprobe) to apply freezing temperatures to the tumour and destroy the cancer cells.

    Interventional procedures guidance
    Published
    24 August 2011
    View recommendations

    Sections for IPG405

  3. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued [GID-TA10927]

    Technology appraisal guidance
    Discontinued

  4. Percutaneous cryotherapy for renal cancer (IPG402)

    Evidence-based recommendations on percutaneous cryotherapy for renal tumours. This involves inserting instruments that apply cold temperatures into the tumour to destroy the cancer cells.

    Interventional procedures guidance
    Published
    27 July 2011
    View recommendations

    Sections for IPG402

  5. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development [GID-TA10745] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  6. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

    Highly specialised technologies guidance
    Published
    20 September 2023
    View recommendations

    Sections for HST28

  7. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    18 July 2018

    Sections for TA531

  8. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued [GID-TA10397]

    Technology appraisal guidance
    Discontinued

  9. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued [GID-TAG398]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    In development [GID-TA10841] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Flexible endoscopic treatment of a pharyngeal pouch (IPG513)

    Evidence-based recommendations on flexible endoscopic treatment of a pharyngeal pouch. This involves improving swallowing by widening the neck of the pouch so that food does not collect in it.

    Interventional procedures guidance
    Published
    23 February 2015
    View recommendations

    Sections for IPG513

  12. Catheterless oesophageal pH monitoring (IPG187)

    Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.

    Interventional procedures guidance
    Published
    26 July 2006
    View recommendations

    Sections for IPG187

  13. Photodynamic therapy for early-stage oesophageal cancer (IPG200)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

    Interventional procedures guidance
    Published
    13 December 2006
    View recommendations

    Sections for IPG200

  14. Stent placement for vena caval obstruction (IPG79)

    Evidence-based recommendations on stent placement for vena caval obstruction. This involves using a catheter to position a stent, which may be self-expanding or balloon-dilated, across the area of narrowing to relieve it.

    Interventional procedures guidance
    Published
    28 July 2004
    View recommendations

    Sections for IPG79

  15. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued [GID-TA10567]

    Technology appraisal guidance
    Discontinued